Dr. Reddy's launches authorized generic versions of Proscar(R) and Zocor(R)

In January 2006, the Company entered into separate agreements withMerck that allowed it to launch the authorized generic versions ofProscar(R) tablets (finasteride) and Zocor(R) tablets (simvastatin).The specific financial terms and conditions of the agreement have notbeen disclosed.

About Dr. Reddy's

Established in 1984, Dr. Reddy's Laboratories (NYSE: RDY) is anemerging global pharmaceutical company with proven researchcapabilities. The Company is vertically integrated with a presenceacross the pharmaceutical value chain. It produces finished dosageforms, active pharmaceutical ingredients and biotechnology productsand markets them globally, with focus on India, US, Europe and Russia.The Company conducts research in the areas of diabetes,cardiovascular, anti-infectives, inflammation and cancer.

Notes to the editor:

Proscar(R) is indicated for the treatment of benign prostatichyperplasia with innovator sales of US$ 393 million (IMS December 2005MAT). The compound patent for Proscar(R) expires on June 19, 2006.Zocor(R) is ZOCOR is indicated to reduce elevated LDL-C and TG levelsin patients with Type IIb hyperlipidemia (where hypercholesterolemiais the major abnormality) with innovator sales of US$ 4.5 billion (IMSDecember 2005 MAT). The '784 compound patent for Zocor(R) expires onJune 23, 2006.